← 홈

CGT · VEGF

4개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
CGTBiologicHistograft Co., Ltd.operatedPreclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 45상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleRochePhase 2

NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy (NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING